Agenus (AGEN) Income from Continuing Operations (2010 - 2026)
Agenus (AGEN) posted quarterly Income from Continuing Operations of 364000.0 for Q1 2026, up 101.38% year-over-year from 180748.9 in Q1 2025, and up 122.05% quarter-over-quarter from 1651000.0 in Q4 2025.
Powered by 
Analysis
Agenus (AGEN) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Agenus' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 364000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 101.38% year-over-year to 364000.0; the TTM figure through Mar 2026 stood at 38312379.0 (up 81.22% YoY), while the FY2025 annual figure was 415080000.0, up 20.05% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 364000.0, up from 1651000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 364000.0 in Q1 2026, with the low at 105528000.0 in Q4 2023.
- The 5-year median for Income from Continuing Operations is 46741000.0 (2023), against an average of 44125370.29.
- The sharpest annual moves came in 2022 and 2026: Income from Continuing Operations plunged 131.71% in 2022, then soared 101.38% in 2026.
- Agenus' Income from Continuing Operations stood at 58053000.0 in 2022, then plunged by 81.78% to 105528000.0 in 2023, then jumped by 55.45% to 47011000.0 in 2024, then jumped by 96.49% to 1651000.0 in 2025, then surged by 122.05% to 364000.0 in 2026.
- Business Quant data shows AGEN's Income from Continuing Operations at 364000.0 in Q1 2026, 1651000.0 in Q4 2025, and 6971379.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Agenus | 344.35 Mn | 344.35 Mn | 34.52 Mn | -3.95 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.95 Mn |
| Mar 31, 2026 | 385,000.00 |
| Dec 31, 2025 | -1.62 Mn |
| Sep 30, 2025 | -17.72 Mn |
| Jun 30, 2025 | -30.00 Mn |
| Mar 31, 2025 | -26.11 Mn |
| Dec 31, 2024 | -46.58 Mn |
| Sep 30, 2024 | -67.23 Mn |
| Jun 30, 2024 | -61.94 Mn |
| Mar 31, 2024 | -62.35 Mn |
| Dec 31, 2023 | -48.38 Mn |
| Sep 30, 2023 | -64.97 Mn |
| Jun 30, 2023 | -73.19 Mn |
| Mar 31, 2023 | -70.93 Mn |
| Dec 31, 2022 | -75.08 Mn |
| Sep 30, 2022 | -57.25 Mn |
| Jun 30, 2022 | -58.30 Mn |
| Mar 31, 2022 | -50.66 Mn |
| Dec 31, 2021 | -70.60 Mn |
| Sep 30, 2021 | 170.96 Mn |